HK1079700A1 - Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands - Google Patents

Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands

Info

Publication number
HK1079700A1
HK1079700A1 HK05112028.6A HK05112028A HK1079700A1 HK 1079700 A1 HK1079700 A1 HK 1079700A1 HK 05112028 A HK05112028 A HK 05112028A HK 1079700 A1 HK1079700 A1 HK 1079700A1
Authority
HK
Hong Kong
Prior art keywords
receptor ligands
glutamate receptor
metabotropic glutamate
quinolinone derivatives
radiolabelled
Prior art date
Application number
HK05112028.6A
Other languages
English (en)
Inventor
Anne Simone Josephine Lesage
Francois Paul Bischoff
Cornelus Gerardus Maria Janssen
Hilde Lavreysen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1079700A1 publication Critical patent/HK1079700A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
HK05112028.6A 2002-03-29 2005-12-28 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands HK1079700A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076254 2002-03-29
PCT/EP2003/003240 WO2003082350A2 (en) 2002-03-29 2003-03-26 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands

Publications (1)

Publication Number Publication Date
HK1079700A1 true HK1079700A1 (en) 2006-04-13

Family

ID=28459531

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05112028.6A HK1079700A1 (en) 2002-03-29 2005-12-28 Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands

Country Status (19)

Country Link
US (1) US7517517B2 (ja)
EP (1) EP1492571A2 (ja)
JP (1) JP4573533B2 (ja)
KR (1) KR101061561B1 (ja)
CN (1) CN1642580B (ja)
AU (1) AU2003226737B2 (ja)
BR (1) BR0308945A (ja)
CA (1) CA2479109C (ja)
EA (1) EA009334B1 (ja)
HK (1) HK1079700A1 (ja)
HR (1) HRP20040870A2 (ja)
IL (1) IL164299A (ja)
MX (1) MXPA04009435A (ja)
NO (1) NO330688B1 (ja)
NZ (1) NZ535438A (ja)
PL (1) PL218788B1 (ja)
UA (1) UA78548C2 (ja)
WO (1) WO2003082350A2 (ja)
ZA (1) ZA200407820B (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
SG150533A1 (en) 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
KR101149031B1 (ko) * 2003-12-10 2012-05-29 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 치환된6-사이클로헥실알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
US7550482B2 (en) 2004-02-27 2009-06-23 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
AU2005259189B2 (en) 2004-06-30 2011-04-21 Janssen Pharmaceutica N.V. Phthalazine derivatives as PARP inhibitors
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
EP1804781A1 (en) * 2004-10-05 2007-07-11 Merz Pharma GmbH & Co.KGaA Novel cyclic and acyclic propenones for treating cns disorders
MX2007010414A (es) * 2005-03-04 2007-09-25 Hoffmann La Roche Derivados de piridin-2-carboxamida como antagonistas de mglur5.
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
PT2203439E (pt) 2007-09-14 2011-02-11 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas
WO2009033702A1 (en) 2007-09-14 2009-03-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
EP2220083B1 (en) * 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2767973T3 (es) 2008-02-29 2020-06-19 Lantheus Medical Imaging Inc Agentes de contraste para aplicaciones que comprenden formación de imágenes de perfusión
US8168644B2 (en) 2008-03-27 2012-05-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
SI2271626T1 (sl) 2008-03-27 2015-03-31 Janssen Pharmaceutica, N.V. Tetrahidrofenantridinoni in tetrahidrociklopentakinolinoni, kot inhibitorji polimerizacije PARP in tubulina
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
US9687571B2 (en) 2009-04-15 2017-06-27 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
ES2409006T3 (es) 2009-05-12 2013-06-24 Janssen Pharmaceuticals Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760741C (en) 2009-05-12 2018-05-01 Addex Pharma S.A. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
DK2534136T3 (en) 2010-02-08 2017-12-04 Lantheus Medical Imaging Inc METHODS OF SYNTHETIZING CONTRAST AGENTS AND INTERMEDIATES THEREOF
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-***并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2668694T3 (es) * 2012-07-27 2018-05-21 Biogen Ma Inc. Derivados de ácido 1-[7-(cis-4-metil-ciclohexiloxi)-8-trifluorometil-naftalen-2-ilmetil]-piperidin-4-carboxílico como moduladores de autotaxina (ATX) para tratar inflamaciones y trastornos autoinmunitarios
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2014048940A2 (en) * 2012-09-28 2014-04-03 Bayer Cropscience Ag Nitrogen-containing heterocyclic compounds for plant disease control
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
EP2909192B1 (en) 2012-10-16 2017-05-17 Janssen Pharmaceutica NV Methylene linked quinolinyl modulators of ror-gamma-t
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
CN106102742A (zh) * 2013-09-13 2016-11-09 因莱塔生物科技有限责任公司 利用细胞外钙调节针对代谢型谷氨酸受体的药物作用
ES2770727T3 (es) 2013-10-15 2020-07-02 Janssen Pharmaceutica Nv Moduladores de quinilonila enlazados a alquilo de ROR(gamma)t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
CN105848483A (zh) 2013-10-15 2016-08-10 詹森药业有限公司 RORγt 的喹啉基调节剂
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
JP6629740B2 (ja) 2014-01-21 2020-01-15 ヤンセン ファーマシューティカ エヌ．ベー． 代謝型グルタミン酸作動性受容体サブタイプ２の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用
CN105949190B (zh) * 2016-07-04 2018-06-29 烟台凯博医药科技有限公司 一种制备1，8-萘啶及衍生物的方法
CN110872252B (zh) * 2019-12-12 2021-06-29 北京成宇化工有限公司 3-甲基喹啉-8-磺酰氯的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2526232A (en) * 1946-10-21 1950-10-17 Parke Davis & Co Substituted hydantoins and methods for obtaining the same
GB1013224A (en) * 1962-06-21 1965-12-15 Ici Ltd Heterocyclic aminoethanols
JPS5566560A (en) * 1978-11-14 1980-05-20 Yoshitomi Pharmaceut Ind Ltd Quinolone derivative
US4348398A (en) * 1980-12-23 1982-09-07 Merck Sharp & Dohme (I.A.) Corp. Quinolinyl ethanolamines
DE3276432D1 (en) * 1981-03-24 1987-07-02 Ciba Geigy Ag Acyl quinolinone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use
GB8307831D0 (en) * 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Triazine derivatives
JPH0776838B2 (ja) * 1988-10-05 1995-08-16 富士ゼロックス株式会社 電子写真感光体及び画像形成方法
US4931270A (en) 1988-07-07 1990-06-05 Nelson Research & Development Method for detecting dopaminergic diseases using fluorine-18 radiolabelled D2 dopamine receptor ligands
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5441963A (en) * 1991-12-20 1995-08-15 Merrell Dow Pharmaceuticals Potentiation of NMDA antagonists
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
JPH0733743A (ja) * 1993-07-22 1995-02-03 Kyorin Pharmaceut Co Ltd ２−アリール−４−キノリノール誘導体
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
AU3414295A (en) * 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
JPH08295690A (ja) * 1995-04-26 1996-11-12 Tokuyama Corp クロメン化合物
US6001331A (en) * 1996-01-24 1999-12-14 Warner-Lambert Company Method of imaging amyloid deposits
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
US6204292B1 (en) * 1997-07-18 2001-03-20 Georgetown University Bicyclic metabotropic glutamate receptor ligands
NZ505207A (en) * 1997-11-21 2003-10-31 Nps Pharma Inc Metabotropic glutamate receptor antagonists for treating central nervous system diseases
JP3494409B2 (ja) * 1998-08-27 2004-02-09 ファイザー・プロダクツ・インク 抗がん剤として有用なアルキニル置換キノリン−２−オン誘導体
JP2000169450A (ja) 1998-09-30 2000-06-20 Kyorin Pharmaceut Co Ltd ６―アリ―ルキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
KR100818541B1 (ko) * 1998-12-23 2008-04-02 얀센 파마슈티카 엔.브이. 1,2-어닐링된 퀴놀린 유도체
TR200201297T2 (tr) * 1999-02-11 2002-06-21 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri.
CA2402096A1 (en) * 2000-03-07 2001-09-13 Takeda Chemical Industries, Ltd. Vasoactive agents
HUP0302167A3 (en) * 2000-10-02 2010-03-29 Janssen Pharmaceutica Nv Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them

Also Published As

Publication number Publication date
CA2479109C (en) 2011-08-02
CN1642580A (zh) 2005-07-20
BR0308945A (pt) 2005-01-04
JP2005524679A (ja) 2005-08-18
WO2003082350A2 (en) 2003-10-09
JP4573533B2 (ja) 2010-11-04
PL371607A1 (en) 2005-06-27
AU2003226737A1 (en) 2003-10-13
KR20040093711A (ko) 2004-11-08
EA009334B1 (ru) 2007-12-28
EP1492571A2 (en) 2005-01-05
ZA200407820B (en) 2005-12-28
MXPA04009435A (es) 2005-01-25
US7517517B2 (en) 2009-04-14
KR101061561B1 (ko) 2011-09-02
HRP20040870A2 (en) 2005-06-30
NO330688B1 (no) 2011-06-06
US20060083676A1 (en) 2006-04-20
PL218788B1 (pl) 2015-01-30
EA200401285A1 (ru) 2005-02-24
UA78548C2 (en) 2007-04-10
NO20044635L (no) 2004-10-27
CN1642580B (zh) 2010-05-26
WO2003082350A3 (en) 2004-03-04
AU2003226737B2 (en) 2008-09-04
IL164299A0 (en) 2005-12-18
NZ535438A (en) 2006-08-31
IL164299A (en) 2010-11-30
CA2479109A1 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
HK1079700A1 (en) Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
HK1089438A1 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
HUS1400047I1 (hu) Kinolin származékok és azok alkalmazása mikrobakteriális inhibitorként
PL372871A1 (en) Quinolinone derivatives
HUP0400249A3 (en) Pyridine derivatives as 5-ht receptor ligands and uses thereof
HK1074439A1 (en) Quinoline derivatives and their use as 5-ht6 ligands
AU2167002A (en) Indoline derivatives and their use as 5-ht2 receptor ligands
IL156487A0 (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
HK1085205A1 (en) Benzimidazole quinolinones and uses thereof
PL377215A1 (pl) Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
HK1045683A1 (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
IL172467A0 (en) Quinolyl amide derivatives as ccr-5 antagonists
IL157412A0 (en) Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
GB0117577D0 (en) Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
HK1088261A1 (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
EP1406631A4 (en) DOPAMINE RECEPTOR LIGANDS AND CORRESPONDING THERAPEUTIC METHODS
HK1071364A1 (en) Quinoline derivatives
GB0117531D0 (en) Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
AU2002345707A1 (en) Dopamine receptor ligands and therapeutic methods based thereon
HK1077577A1 (en) Tetrahydroquinoline derivatives
SI1663982T1 (sl) Aminokinolinski derivati in njihova uporaba kot adenozin A3 ligandi
IL147592A0 (en) Reversible trousers

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150326